A new partnership has been formed to create and develop a centre carrying out research into Alzheimer’s Disease and dementia.
The pioneering programme, between the Cheltenham based charity Cobalt and ²gether NHS Foundation Trust, will ensure that research into the illnesses is undertaken in Gloucestershire and Herefordshire.
The research results will contribute towards improving standards of care and treatment locally, and also to the wider research environment nationally and internationally.
Professor Jane Melton, Director of Engagement and Integration for ²gether, said: “This is a very exciting development for both of our organisations, as we collectively have extensive knowledge and experience of working with and supporting people with dementia.
“By joining together we hope to develop world class, practice based, research and development locally and provide service innovation for the benefit of patients, families and society in general.
“We have recently established a new Research Centre and base for our Managing Memory service on our Charlton Lane site, in Cheltenham, which provides the perfect opportunity for this collaboration to begin.
“Although we’ve always enjoyed a good relationship with Cobalt, particularly in terms of diagnostic imaging, this research partnership formalises our working arrangements and we’re very excited about what the future will bring.”
Peter Sharpe, Chief Executive of Cobalt, said: “We have been working closely to support the dementia service by providing cutting edge diagnostic imaging. We are very excited to enter into this research partnership, as by working together we can expand the boundaries far beyond what would normally be available.”
Professor Gordon Wilcock, Emeritus Professor of Geratology -University of Oxford, and Honorary Consultant Physician at ²gether NHS Foundation Trust, said: “Bringing together the Trust’s patient base, and Cobalt’s state of the art imaging facilities and support, creates an important opportunity which will allow NHS patients with Alzheimer’s disease or one of the other dementias, and their families, to take part in research if they would like to, including the evaluation of new treatments and better diagnostic tests.
“I am delighted to have contributed to this development and look forward to working with both organisations in the future.”